NCT02341378View on ClinicalTrials.gov

Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

June 30, 2010

Study Completion Date

October 31, 2010

Conditions
Degenerative Arthritis
Interventions
BIOLOGICAL

TissueGene-C(Low dose)

TissueGene-C at 6.0x10\^6 cells

BIOLOGICAL

TissueGene-C(High dose)

TissueGene-C at 1.8x10\^7 cells

Trial Locations (3)

135-710

Samsung Medical Center, Gangnam-gu

110-744

Seoul National Univ. Hospital, Seoul

138-736

Asan Medical Center, Seoul

Sponsors

Lead Sponsor

Kolon Life Science
All Listed Sponsors
lead

Kolon Life Science

INDUSTRY